The biological mechanism explaining why the prognostic role of VEGF-C in operable breast cancer differs when it is measured in tumor tissue (by immunohistochemistry or mRNA analysis) and when it is measured in peripheral blood is unknown. Here, VEGFC is linked to breast carcinoma.